Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 4.505M
March 31, 2026 -11.62M
December 31, 2025 -100.79M
September 30, 2025 -99.17M
June 30, 2025 -98.41M
March 31, 2025 -18.22M
December 31, 2024 -101.33M
September 30, 2024 1.869M
June 30, 2024 0.099M
March 31, 2024 -16.84M
December 31, 2023 -0.45M
September 30, 2023 0.108M
June 30, 2023 -4.051M
March 31, 2023 -8.669M
December 31, 2022 317.84M
September 30, 2022 -1.959M
June 30, 2022 -2.011M
March 31, 2022 -2.179M
December 31, 2021 -2.10M
September 30, 2021 -1.726M
June 30, 2021 -0.715M
March 31, 2021 -34.79M
December 31, 2020 -9.373M
September 30, 2020 -3.84M
June 30, 2020 -4.916M
Date Value
March 31, 2020 -3.732M
December 31, 2019 -2.823M
September 30, 2019 -1.90M
June 30, 2019 -72.93M
March 31, 2019 -1.231M
December 31, 2018 -0.934M
September 30, 2018 -1.217M
June 30, 2018 -1.813M
March 31, 2018 -0.704M
December 31, 2017 1.15M
September 30, 2017 -1.519M
June 30, 2017 -1.827M
March 31, 2017 -11.25M
December 31, 2016 -12.26M
September 30, 2016 -16.09M
June 30, 2016 -0.928M
March 31, 2016 -0.944M
December 31, 2015 -1.042M
September 30, 2015 -3.014M
June 30, 2015 5.514M
March 31, 2015 -0.459M
December 31, 2014 -0.361M
September 30, 2014 -7.33M
June 30, 2014 5.399M
March 31, 2014 -0.005M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Biomerica, Inc. 0.871M
Univec, Inc. 0.0157M
Indivior Pharmaceuticals, Inc. -172.64M
Zomedica Corp. 0.00
Bristol Myers Squibb Co. -2.63B